<!DOCTYPE html>
<html class="client-js"><head>
  <meta charset=UTF-8"UTF-8">
  <title>Iduronidase</title>
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <script>
    function importScript() { return 1 } // this is to avoid the error from site.js
  </script>
  <link rel="canonical" href="https://en.wikipedia.org/wiki/Iduronidase">
  <link href="../-/s/css_modules/ext.cite.ux-enhancements.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/ext.cite.ux-enhancements.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/ext.cite.styles.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/ext.cite.styles.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/fi000001.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/skins.minerva.base.reset|skins.minerva.content.styles|ext.cite.style|site.styles|mobile.app.pagestyles.android|mediawiki.page.gallery.styles|mediawiki.skinning.content.parsoid.css" rel="stylesheet" type="text/css" class="">
  <link href="../-/s/css_modules/style.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/style.css" rel="stylesheet" type="text/css" class=""><link href="../-/s/css_modules/content.parsoid.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/content.parsoid.css" rel="stylesheet" type="text/css" class=""><link href="../-/s/css_modules/inserted_style.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/inserted_style.css" rel="stylesheet" type="text/css" class="">
  <script src="../-/j/js_modules/script.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/script.js" class=""></script><script src="../-/j/js_modules/masonry.min.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/masonry.min.js" class=""></script><script src="../-/j/js_modules/article_list_home.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/article_list_home.js" class=""></script><script src="../-/j/js_modules/images_loaded.min.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/images_loaded.min.js" class=""></script><script src="../-/j/js_modules/node_module/details-element-polyfill/dist/details-element-polyfill.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/node_module/details-element-polyfill/dist/details-element-polyfill.js" class=""></script>
<link type="root" href=""></head>

<body class="mediawiki mw-hide-empty-elt ns-0 ns-subject stable skin-minerva action-view animations">
  <div id="mw-mf-viewport" class="feature-header-v2">
    <div id="mw-mf-page-center">
      <div id="content" class="mw-body">
        <a id="top"></a>
        <div id="bodyContent" class="content mw-parser-output">
          
          <div id="mw-content-text" style="direction: ltr;"><h1 class="section-heading" tabindex="0" aria-haspopup="true" data-section-id="0">
  <span class="mw-headline" id="title_0">Iduronidase</span>
</h1>
<div id="mf-section-0" class="mf-section-0" aria-pressed="true" aria-expanded="true">
  <p><b>Iduronidase</b> (EC<span> </span><a href="javascript:if(confirm('https://enzyme.expasy.org/EC/3.2.1.76  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://enzyme.expasy.org/EC/3.2.1.76'" tppabs="https://enzyme.expasy.org/EC/3.2.1.76" class="external text external">3.2.1.76</a>, <i>L-iduronidase</i>, <i>alpha-L-iduronidase</i>, <i>laronidase</i>), sold as <b>Aldurazyme</b>, is an enzyme with the systematic name <i>glycosaminoglycan alpha-L-iduronohydrolase</i>.<span class="mw-ref" id="cite_ref-3"><a href="#cite_note-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span><span class="mw-ref" id="cite_ref-4"><a href="#cite_note-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span><span class="mw-ref" id="cite_ref-5"><a href="#cite_note-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span> This enzyme catalyses the hydrolysis of unsulfated alpha-L-iduronosidic linkages in <a href="Dermatan_sulfate.htm" tppabs="https://ptable.com/wiki/compounds/A/Dermatan_sulfate" title="Dermatan sulfate">dermatan sulfate</a>.<span class="mw-ref" id="cite_ref-Aldurazyme_6-0"><a href="#cite_note-Aldurazyme-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span></p>

<table class="infobox" style="width:22em"><tbody><tr><th colspan="2" style="text-align:center;font-size:125%;font-weight:bold">iduronidase, α-L-</th></tr><tr><th colspan="2" style="text-align:center;background-color: #ddd">Identifiers</th></tr><tr><th scope="row" style="background-color: #e7dcc3">Symbol</th><td style="background-color: #eee">IDUA</td></tr><tr><th scope="row" style="background-color: #e7dcc3">NCBI gene</th><td style="background-color: #eee"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/gene?cmd=retrieve&dopt=default&list_uids=3425&rn=1  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/gene?cmd=retrieve&dopt=default&list_uids=3425&rn=1'" tppabs="https://www.ncbi.nlm.nih.gov/gene?cmd=retrieve&dopt=default&list_uids=3425&rn=1" class="external text external">3425</a></td></tr><tr><th scope="row" style="background-color: #e7dcc3">HGNC</th><td style="background-color: #eee"><a href="javascript:if(confirm('https://www.genenames.org/data/gene-symbol-report/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5391'" tppabs="https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5391" class="external text external">5391</a></td></tr><tr><th scope="row" style="background-color: #e7dcc3">OMIM</th><td style="background-color: #eee"><a href="javascript:if(confirm('https://omim.org/252800  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://omim.org/252800'" tppabs="https://omim.org/252800" class="external text external">252800</a></td></tr><tr><th scope="row" style="background-color: #e7dcc3">RefSeq</th><td style="background-color: #eee"><a href="javascript:if(confirm('https://genome.ucsc.edu/cgi-bin/hgTracks?Submit=Submit&position=NM_000203&rn=1  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://genome.ucsc.edu/cgi-bin/hgTracks?Submit=Submit&position=NM_000203&rn=1'" tppabs="https://genome.ucsc.edu/cgi-bin/hgTracks?Submit=Submit&position=NM_000203&rn=1" class="external text external">NM_000203</a></td></tr><tr><th scope="row" style="background-color: #e7dcc3">UniProt</th><td style="background-color: #eee"><a href="javascript:if(confirm('https://www.uniprot.org/uniprot/P35475  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.uniprot.org/uniprot/P35475'" tppabs="https://www.uniprot.org/uniprot/P35475" class="external text external">P35475</a></td></tr><tr><th colspan="2" style="text-align:center;background-color: #ddd">Other data</th></tr><tr><th scope="row" style="background-color: #e7dcc3">EC number</th><td style="background-color: #eee"><a href="javascript:if(confirm('https://www.genome.jp/dbget-bin/www_bget?enzyme+3.2.1.76  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.genome.jp/dbget-bin/www_bget?enzyme+3.2.1.76'" tppabs="https://www.genome.jp/dbget-bin/www_bget?enzyme+3.2.1.76" class="external text external">3.2.1.76</a></td></tr><tr><th scope="row" style="background-color: #e7dcc3">Locus</th><td style="background-color: #eee">Chr. 4 <i><a href="javascript:if(confirm('https://omim.org/search/?index=geneMap&search=4p16.3  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://omim.org/search/?index=geneMap&search=4p16.3'" tppabs="https://omim.org/search/?index=geneMap&search=4p16.3" class="external text external">p16.3</a></i></td></tr></tbody></table><span>
</span>
<table class="infobox" style="width:22em;border-spacing:2px;"><caption>Laronidase<br><span style="font-size:85%; font-weight:normal;"><abbr>INN</abbr>:</span> Laronidase</caption><tbody><tr><th colspan="2" style="text-align:center;background:#ddd">Clinical data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Trade names</th><td>Aldurazyme</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Other names</th><td>alpha-L-Idosiduronase, Laronidase (genetical recombination) (JAN) (JAN <small><abbr>JP</abbr></small>)</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">AHFS/Drugs.com</th><td><span><a href="javascript:if(confirm('https://www.drugs.com/monograph/laronidase.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/monograph/laronidase.html'" tppabs="https://www.drugs.com/monograph/laronidase.html" class="external text external">Monograph</a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">License data</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">US</abbr></small><span>&nbsp;</span>DailyMed:<span>&nbsp;</span><span><a href="javascript:if(confirm('https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Laronidase  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Laronidase'" tppabs="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Laronidase" class="external text external">Laronidase</a></span></li></ul></div>
</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Pregnancy<br>category</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">AU</abbr>:</small><span> </span>B2<span> </span><span class="mw-ref" id="cite_ref-Drugs.com_pregnancy_1-0"><a href="#cite_note-Drugs.com_pregnancy-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span></li>
<li><small><abbr class="country-name">US</abbr>:</small><span> </span>B (No risk in non-human studies)<span> </span><span class="mw-ref" id="cite_ref-Drugs.com_pregnancy_1-1"><a href="#cite_note-Drugs.com_pregnancy-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span></li></ul>

<ul></ul>
</div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Routes of<br>administration</th><td>Intravenous (IV)</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ATC code</th><td><div class="plainlist"><ul><li>A16AB05<span> </span>(<span><a href="javascript:if(confirm('https://www.whocc.no/atc_ddd_index/?code=A16AB05  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.whocc.no/atc_ddd_index/?code=A16AB05'" tppabs="https://www.whocc.no/atc_ddd_index/?code=A16AB05" class="external text external">WHO</a></span>)<span> </span></li></ul></div></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Legal status</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Legal status</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">UK</abbr>:</small><span> </span>POM (Prescription only)<span> </span><span class="mw-ref" id="cite_ref-2"><a href="#cite_note-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span></li>
<li><small><abbr class="country-name">US</abbr>:</small><span> </span>℞-only<span> </span></li>
<li>In<span>&nbsp;</span>general: ℞<span>&nbsp;</span>(Prescription only)</li></ul></div>
</td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Identifiers</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">CAS Number</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.commonchemistry.org/ChemicalDetail.aspx?ref=210589-09-6  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.commonchemistry.org/ChemicalDetail.aspx?ref=210589-09-6'" tppabs="http://www.commonchemistry.org/ChemicalDetail.aspx?ref=210589-09-6" class="external text external">210589-09-6</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">DrugBank</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.drugbank.ca/drugs/DB00090  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugbank.ca/drugs/DB00090'" tppabs="https://www.drugbank.ca/drugs/DB00090" class="external text external">DB00090</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">UNII</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=WP58SVM6R4  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=WP58SVM6R4'" tppabs="https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=WP58SVM6R4" class="external text external">WP58SVM6R4</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">KEGG</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.kegg.jp/entry/D04670  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.kegg.jp/entry/D04670'" tppabs="https://www.kegg.jp/entry/D04670" class="external text external">D04670</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChEMBL</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL1201595  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL1201595'" tppabs="https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL1201595" class="external text external">ChEMBL1201595</a></span></li></ul></div></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Chemical and physical data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Formula</th><td><span>C</span><sub>3567</sub><span>H</span><sub>5645</sub><span>N</span><sub>921</sub><span>O</span><sub>1261</sub><span>P</span><sub>4</sub><span>S</span><sub>12</sub></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Molar mass</th><td><span class="nowrap">82<span style="margin-left:.25em;">117</span>.20</span><span>&nbsp;</span>g·mol<sup>−1</sup></td></tr></tbody></table>

<p>It is a glycoprotein enzyme found in the lysosomes of cells. It is involved in the degeneration of glycosaminoglycans such as <a href="Dermatan_sulfate.htm" tppabs="https://ptable.com/wiki/compounds/A/Dermatan_sulfate" title="Dermatan sulfate">dermatan sulfate</a> and <a href="Heparan_sulfate.htm" tppabs="https://ptable.com/wiki/compounds/A/Heparan_sulfate" title="Heparan sulfate">heparan sulfate</a>. The enzyme acts by hydrolyzing the terminal alpha-<small>L</small>-iduronic acid residues of these molecules, degrading them. The protein is reported as having a mass of approximately 83 kilodaltons.<span class="mw-ref" id="cite_ref-Aldurazyme_6-1"><a href="#cite_note-Aldurazyme-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span></p>


</div><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Pathology">Pathology</h2></summary>
    
<p>A deficiency in the IDUA protein is associated with mucopolysaccharidoses (MPS). MPS, a type of lysosomal storage disease, is typed I through VII. Type I is known as Hurler syndrome and type I,S is known as Scheie syndrome, which has a milder prognosis compared to Hurler's. In this syndrome, glycosaminoglycans accumulate in the lysosomes and cause substantial disease in many different tissues of the body. IDUA mutations result in the MPS 1 phenotype, which is inherited in an autosomal recessive fashion.<span class="mw-ref" id="cite_ref-7"><a href="#cite_note-7" style="counter-reset: mw-Ref 7;"><span class="mw-reflink-text">[7]</span></a></span>
The defective alpha-L-iduronidase results in an accumulation of heparan and dermatan sulfate within phagocytes, endothelium, smooth muscle cells, neurons, and fibroblasts. Under electron microscopy these structures present as laminated structures called Zebra bodies.</p>

<p>Prenatal diagnosis of this enzyme deficiency is possible.</p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Aldurazyme">Aldurazyme</h2></summary>
    


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="General">General</h3></summary>
    
<p>Aldurazyme is the name of the commercialized variant of the enzyme iduronidase, which hydrolyzes the alpha-L-iduronic acid residues of <a href="Dermatan_sulfate.htm" tppabs="https://ptable.com/wiki/compounds/A/Dermatan_sulfate" title="Dermatan sulfate">dermatan sulfate</a> and heparin sulfate.  Produced in Chinese hamster ovaries by recombinant DNA technology, Aldurazyme is the manufactured by BioMarin Pharmaceutical Inc. and distributed by Genzyme Corporation (a subsidiary of Sanofi). Aldurazyme is administered as a slow intravenous infusion. The recombinant enzyme is 628 amino acids in length with 6 N-linked oligosaccharide modification sites and two oligosaccharide chains terminating in mannose sugars.<span class="mw-ref" id="cite_ref-Aldurazyme_6-2"><a href="#cite_note-Aldurazyme-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Medical_use">Medical use</h3></summary>
    
<p>Aldurazyme is indicated in the US for people with Hurler and Hurler-Scheie forms of Mucopolysaccharidosis I (MPS I) and for people with the Scheie form who have moderate to severe symptoms.<span class="mw-ref" id="cite_ref-Aldurazyme_FDA_label_8-0"><a href="#cite_note-Aldurazyme_FDA_label-8" style="counter-reset: mw-Ref 8;"><span class="mw-reflink-text">[8]</span></a></span></p>

<p>Aldurazyme is indicated in the EU for long-term enzyme replacement therapy in patients with a confirmed diagnosis of mucopolysaccharidosis I (MPS I; alpha-L-iduronidase deficiency) to treat the nonneurological manifestations of the disease.<span class="mw-ref" id="cite_ref-Aldurazyme_EPAR_9-0"><a href="#cite_note-Aldurazyme_EPAR-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span></p>

<p>Aldurazyme was approved for medical use in the United States and in the European Union in 2003.<span class="mw-ref" id="cite_ref-10"><a href="#cite_note-10" style="counter-reset: mw-Ref 10;"><span class="mw-reflink-text">[10]</span></a></span><span class="mw-ref" id="cite_ref-11"><a href="#cite_note-11" style="counter-reset: mw-Ref 11;"><span class="mw-reflink-text">[11]</span></a></span><span class="mw-ref" id="cite_ref-Aldurazyme_FDA_label_8-1"><a href="#cite_note-Aldurazyme_FDA_label-8" style="counter-reset: mw-Ref 8;"><span class="mw-reflink-text">[8]</span></a></span><span class="mw-ref" id="cite_ref-Aldurazyme_EPAR_9-1"><a href="#cite_note-Aldurazyme_EPAR-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Pre-clinical_work">Pre-clinical work</h3></summary>
    
<p>Dosing for human clinical studies was based on canine MPS I studies.<span class="mw-ref" id="cite_ref-Clinical_12-0"><a href="#cite_note-Clinical-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Clinical_trials">Clinical trials</h3></summary>
    
<p>Three clinical trials were performed to establish the pharmacology, efficacy, and safety of weekly intravenous administration of the drug.  These studies included a Phase I open-label study, a Phase III randomized, double-blind, placebo-controlled study, and a Phase III open-label extension study.  A Phase II Young Pediatric study was also conducted.<span class="mw-ref" id="cite_ref-Clinical_12-1"><a href="#cite_note-Clinical-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></span></p>

<p>Clinical trials and post-market safety data indicate that the most common adverse side effect of Aldurazyme is allergic reaction.<span class="mw-ref" id="cite_ref-Clinical_12-2"><a href="#cite_note-Clinical-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></span> In order to prevent allergic reaction and respiratory distress, the packet insert of Aldurazyme suggests that patients be administered antihistamines before infusion.<span class="mw-ref" id="cite_ref-Clinical_12-3"><a href="#cite_note-Clinical-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></span> Allergic reaction occurs in approximately 1% of patients.  It is recommended that patients who are high-risk for respiratory distress be given their infusion in a facility equipped to deal with an anaphylactic response.<span class="mw-ref" id="cite_ref-Clinical_12-4"><a href="#cite_note-Clinical-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></span> (High-risk factors include sleep apnea, respiratory impairment, respiratory illness, or previous experience with allergic reaction to Aldurazyme.  It is noted that risk-benefit must be weighed for patients with history of severe allergic response as to whether the drug should be administered again.)<span class="mw-ref" id="cite_ref-Clinical_12-5"><a href="#cite_note-Clinical-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></span> In a 2002 memorandum, Melanie Hartsough, Ph.D., DTP of the FDA's Department of Health and Human Services stated, "Aggregation of product could enhance immune responses, specifically neutralizing antibody, which may limit the response to therapy, whereas highly deaggregated product may induce immune tolerance." It appears that she then went on to ask for further justification of some relevant aspect of the production process, though the majority of this particular memorandum has not been publicly released and it is unclear as to whether this concern is relevant to the high rate of allergic response to this drug.<span class="mw-ref" id="cite_ref-13"><a href="#cite_note-13" style="counter-reset: mw-Ref 13;"><span class="mw-reflink-text">[13]</span></a></span></p>

<p>Additionally, it is recommended that patients be administered antipyretics before use. According to Aldurazyme's website, the most common adverse effects observed in a 26-week, placebo-controlled clinical trial of patients 6 years old or older are  flushing, pyrexia, headache, and rash.  Flushing was noted in 23% of patients, or five people, in this relatively small clinical study. This trial was extended.  In the extension, it was noted that abdominal pain and infusion-site reaction occurred in some patients.<span class="mw-ref" id="cite_ref-Clinical_12-6"><a href="#cite_note-Clinical-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></span></p>

<p>The website also states that in a 52-week open-label uncontrolled clinical trial, the most common serious reactions in children younger than 6 were "otitis media (20%), and central venous catherization required for ALDURAZYME infusion (15%). The most commonly reported adverse reactions in patients 6 years and younger were infusion reactions reported in 35% (7 of 20) of patients and included pyrexia (30%), chills (20%), blood pressure increased (10%), tachycardia (10%), and oxygen saturation decreased (10%). Other commonly reported infusion reactions occurring in ≥5% of patients were pallor, tremor, respiratory distress, wheezing, crepitations (pulmonary), pruritus, and rash."<span class="mw-ref" id="cite_ref-Clinical_12-7"><a href="#cite_note-Clinical-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></span></p>

<p>A Phase IV clinical trial is currently recruiting participants to investigate whether Aldurazyme passes through breastmilk and whether it has any effect on nursing infants.<span class="mw-ref" id="cite_ref-14"><a href="#cite_note-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></span> </p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Regulation">Regulation</h3></summary>
    
<p>Aldurazyme was the first drug approved by the United States Food and Drug Administration to be marketed as a treatment for MPS I.  It was approved in April 2003.  Marketing authorization in the European Union was granted in June 2003 by the European Commission.  Aldurazyme enjoys orphan drug status in both the United States and the European Union, though in both its orphan drug exclusivity period has expired.  (Orphan drug exclusivity, which prevents the FDA or similar European body from approving the same drug proposed by another company for the same listed use lasts only seven years in the United States and ten years in the European Union.)  Aldurazyme was granted orphan designation for Treatment of patients with mucopolysaccharidosis-I on September 24, 1997.<span class="mw-ref" id="cite_ref-biomarin_15-0"><a href="#cite_note-biomarin-15" style="counter-reset: mw-Ref 15;"><span class="mw-reflink-text">[15]</span></a></span><span class="mw-ref" id="cite_ref-SEC_10-K_Feb_2011_16-0"><a href="#cite_note-SEC_10-K_Feb_2011-16" style="counter-reset: mw-Ref 16;"><span class="mw-reflink-text">[16]</span></a></span><span class="mw-ref" id="cite_ref-17"><a href="#cite_note-17" style="counter-reset: mw-Ref 17;"><span class="mw-reflink-text">[17]</span></a></span></p>

<p>As of 2014, Aldurazyme was mandated to be produced using Good Manufacturing Practices (GMP) and, along with several other recombinant enzyme products produced by Biomarin, was manufactured at the production facility located in Novato, California.  Both packaging and vialing were performed by contractors. All suppliers and contractors also are mandated to follow GMP, and they, as well as BioMarin, are subject to inspection and review. BioMarin's facility has received both FDA and European Commission approval.<span class="mw-ref" id="cite_ref-D_2014_18-0"><a href="#cite_note-D_2014-18" style="counter-reset: mw-Ref 18;"><span class="mw-reflink-text">[18]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Commercialization_plan">Commercialization plan</h3></summary>
    
<p>Aldurazyme is manufactured by BioMarin in California. It is commercialized and distributed by Genzyme in the United States, the European Union, and worldwide.<span class="mw-ref" id="cite_ref-biomarin_15-1"><a href="#cite_note-biomarin-15" style="counter-reset: mw-Ref 15;"><span class="mw-reflink-text">[15]</span></a></span>  The patent for Aldurazyme was filed by BioMarin on November 12, 1999, patent no. US 6426208 B1, "Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof".<span class="mw-ref" id="cite_ref-patent_19-0"><a href="#cite_note-patent-19" style="counter-reset: mw-Ref 19;"><span class="mw-reflink-text">[19]</span></a></span></p>

<p>Aldurazyme yielded a net $105.6 million net product revenue out of $738.4 million in net profit revenues in 2014, $83.6 million out of $538.4 million in 2013, and $82.2 million out of $496.5 million in 2012, making it BioMarin's third-most profitable product behind Naglazyme and Kuvan.<span class="mw-ref" id="cite_ref-D_2014_18-1"><a href="#cite_note-D_2014-18" style="counter-reset: mw-Ref 18;"><span class="mw-reflink-text">[18]</span></a></span> In 2011, Aldurazyme yielded a net product revenue of $82.8 million out of $437.6 million net revenue, and in 2010 it netted $71.2 million out of $369.7 million in net product revenues.<span class="mw-ref" id="cite_ref-20"><a href="#cite_note-20" style="counter-reset: mw-Ref 20;"><span class="mw-reflink-text">[20]</span></a></span> Aldurazyme netted $70.2 million in profit revenues in 2009 out of a total $315.7 $72.5 million in revenue were netted in 2008 out of Biomarin's $251.9 million in product revenues that year.<span class="mw-ref" id="cite_ref-SEC_10-K_Feb_2011_16-1"><a href="#cite_note-SEC_10-K_Feb_2011-16" style="counter-reset: mw-Ref 16;"><span class="mw-reflink-text">[16]</span></a></span><span class="mw-ref" id="cite_ref-21"><a href="#cite_note-21" style="counter-reset: mw-Ref 21;"><span class="mw-reflink-text">[21]</span></a></span></p>

<p>BioMarin described its business strategy as the following in their 2014 United States Securities and Exchange Commission Form 10-K:</p>

<style data-mw-deduplicate="TemplateStyles:r960796168">.mw-parser-output .templatequote{overflow:hidden;margin:1em 0;padding:0 40px}.mw-parser-output .templatequote .templatequotecite{line-height:1.5em;text-align:left;padding-left:1.6em;margin-top:0}</style><blockquote class="templatequote"><p>BioMarin Pharmaceutical Inc. (BioMarin, we, us or our) develops and commercializes innovative pharmaceuticals for serious diseases and medical conditions. We select product candidates for diseases and conditions that represent a significant unmet medical need, have well-understood biology and provide an opportunity to be first-to-market or offer a significant benefit over existing products.</p><div class="templatequotecite">—<span> </span><cite>BioMarin Pharmaceuticals' 2014 United States Securities and Exchange Commission Form 10-K</cite></div></blockquote>

<p>Based on this business model, it is easy to understand why BioMarin would have targeted a disease like MPS I for treatment.  It is, as described, an orphan condition with a well-defined mechanism.  Furthermore, before the development of Aldurazyme, there were no drugs to treat MPS I, allowing BioMarin to be first-to-market with its new pharmaceutical.  Since the release of Aldurazyme, one more drug has been released to treat MPS; Elaprase is a treatment for MPS II.</p>

<p>In 2016, Aldurazyme had an average cost-per-patient of $355,816.<span class="mw-ref" id="cite_ref-22"><a href="#cite_note-22" style="counter-reset: mw-Ref 22;"><span class="mw-reflink-text">[22]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Collaboration_between_BioMarin_and_Genzyme">Collaboration between BioMarin and Genzyme</h3></summary>
    
<p>BioMarin/Genzyme is a 50/50 Limited Liability Company which co-owns the intellectual rights to Aldurazyme and works collaboratively on research and development.  BioMarin is responsible for the production of Aldurazyme.  It sells the finished product to Genzyme, which is a fully owned subsidiary of Sanofi.  Genzyme pays a 39.5% - 50% royalty quarterly on worldwide net product sales to BioMarin.  A portion of this royalty is considered to be product transfer royalties, meaning that if any Aldurazyme goes unsold, BioMarin merely retains the product transfer royalty, while not receiving any further royalties.  Only in the case of defective product  is Genzyme reimbursed for Aldurazyme product.<span class="mw-ref" id="cite_ref-D_2014_18-2"><a href="#cite_note-D_2014-18" style="counter-reset: mw-Ref 18;"><span class="mw-reflink-text">[18]</span></a></span></p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="References">References</h2></summary>
    
<div class="reflist " style=" list-style-type: decimal;">
<div class="mw-references-wrap mw-references-columns"><ol class="mw-references references"><li id="cite_note-Drugs.com_pregnancy-1"> <span id="mw-reference-text-cite_note-Drugs.com_pregnancy-1" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.drugs.com/pregnancy/laronidase.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/pregnancy/laronidase.html'" tppabs="https://www.drugs.com/pregnancy/laronidase.html" class="external text external">"Laronidase (Aldurazyme) Use During Pregnancy"</a>. <i>Drugs.com</i>. 11 December 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">14 April</span> 2020</span>.</cite></span></li><li id="cite_note-2"> <span id="mw-reference-text-cite_note-2" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.medicines.org.uk/emc/product/216/smpc  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.medicines.org.uk/emc/product/216/smpc'" tppabs="https://www.medicines.org.uk/emc/product/216/smpc" class="external text external">"Aldurazyme 100 U/ml concentrate for solution for infusion - Summary of Product Characteristics (SmPC)"</a>. <i>(emc)</i>. 2 January 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">14 April</span> 2020</span>.</cite></span></li><li id="cite_note-3"> <span id="mw-reference-text-cite_note-3" class="mw-reference-text"><cite id="CITEREFMatalonCifonelliDorfman1971" class="citation journal cs1">Matalon R, Cifonelli JA, Dorfman A (January 1971). "L-iduronidase in cultured human fibroblasts and liver". <i>Biochemical and Biophysical Research Communications</i>. <b>42</b> (2): 340–5. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2F0006-291x%2871%2990108-2  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2F0006-291x%2871%2990108-2'" tppabs="https://doi.org/10.1016%2F0006-291x%2871%2990108-2" class="external text external">10.1016/0006-291x(71)90108-2</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/4993544  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/4993544'" tppabs="https://pubmed.ncbi.nlm.nih.gov/4993544" class="external text external">4993544</a>.</cite></span></li><li id="cite_note-4"> <span id="mw-reference-text-cite_note-4" class="mw-reference-text"><cite id="CITEREFRomeGarvinNeufeld1978" class="citation journal cs1">Rome LH, Garvin AJ, Neufeld EF (August 1978). "Human kidney alpha-L-iduronidase: purification and characterization". <i>Archives of Biochemistry and Biophysics</i>. <b>189</b> (2): 344–53. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2F0003-9861%2878%2990221-7  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2F0003-9861%2878%2990221-7'" tppabs="https://doi.org/10.1016%2F0003-9861%2878%2990221-7" class="external text external">10.1016/0003-9861(78)90221-7</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/30407  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/30407'" tppabs="https://pubmed.ncbi.nlm.nih.gov/30407" class="external text external">30407</a>.</cite></span></li><li id="cite_note-5"> <span id="mw-reference-text-cite_note-5" class="mw-reference-text"><cite id="CITEREFSrivastavaHudsonSeymourWeissman1978" class="citation journal cs1">Srivastava RM, Hudson N, Seymour FR, Weissman B (1978). "Preparation of (aryl <span>α</span>-L-idopyranosid)uronic acids". <i>Carbohydr. Res</i>. <b>60</b>: 315–326. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fs0008-6215%2878%2980038-x  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fs0008-6215%2878%2980038-x'" tppabs="https://doi.org/10.1016%2Fs0008-6215%2878%2980038-x" class="external text external">10.1016/s0008-6215(78)80038-x</a>.</cite></span></li><li id="cite_note-Aldurazyme-6"> <span id="mw-reference-text-cite_note-Aldurazyme-6" class="mw-reference-text"><a href="javascript:if(confirm('https://www.fda.gov/downloads/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/approvalapplications/therapeuticbiologicapplications/ucm083688.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/downloads/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/approvalapplications/therapeuticbiologicapplications/ucm083688.pdf'" tppabs="https://www.fda.gov/downloads/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/approvalapplications/therapeuticbiologicapplications/ucm083688.pdf" class="external text external">Aldurazyme (Laronidase)</a>. BioMarin Pharmaceuticals Inc.  FDA website. Retrieved December 6, 2015.</span></li><li id="cite_note-7"> <span id="mw-reference-text-cite_note-7" class="mw-reference-text"><cite id="CITEREFScottNelsonLitjensHopwood1993" class="citation journal cs1">Scott HS, Nelson PV, Litjens T, Hopwood JJ, Morris CP (September 1993). "Multiple polymorphisms within the alpha-L-iduronidase gene (IDUA): implications for a role in modification of MPS-I disease phenotype". <i>Human Molecular Genetics</i>. <b>2</b> (9): 1471–3. doi:<a href="javascript:if(confirm('https://doi.org/10.1093%2Fhmg%2F2.9.1471  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1093%2Fhmg%2F2.9.1471'" tppabs="https://doi.org/10.1093%2Fhmg%2F2.9.1471" class="external text external">10.1093/hmg/2.9.1471</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/8242073  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/8242073'" tppabs="https://pubmed.ncbi.nlm.nih.gov/8242073" class="external text external">8242073</a>.</cite></span></li><li id="cite_note-Aldurazyme_FDA_label-8"> <span id="mw-reference-text-cite_note-Aldurazyme_FDA_label-8" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a80ac249-cae4-41f3-88bb-344088b20e60  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a80ac249-cae4-41f3-88bb-344088b20e60'" tppabs="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a80ac249-cae4-41f3-88bb-344088b20e60" class="external text external">"Aldurazyme- laronidase injection, solution, concentrate"</a>. <i>DailyMed</i>. 12 December 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">14 April</span> 2020</span>.</cite></span></li><li id="cite_note-Aldurazyme_EPAR-9"> <span id="mw-reference-text-cite_note-Aldurazyme_EPAR-9" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.ema.europa.eu/en/medicines/human/EPAR/aldurazyme  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ema.europa.eu/en/medicines/human/EPAR/aldurazyme'" tppabs="https://www.ema.europa.eu/en/medicines/human/EPAR/aldurazyme" class="external text external">"Aldurazyme EPAR"</a>. <i>European Medicines Agency (EMA)</i><span class="reference-accessdate">. Retrieved <span class="nowrap">14 April</span> 2020</span>.</cite></span></li><li id="cite_note-10"> <span id="mw-reference-text-cite_note-10" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://web.archive.org/web/20170118085125/https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm080438.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20170118085125/https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm080438.htm'" tppabs="https://web.archive.org/web/20170118085125/https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm080438.htm" class="external text external">"Laronidase Product Approval Information - Licensing Action"</a>. <i>U.S. Food and Drug Administration (FDA)</i>. 30 September 2016. Archived from <a href="javascript:if(confirm('https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm080438.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm080438.htm'" tppabs="https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm080438.htm" class="external text external">the original</a> on 18 January 2017<span class="reference-accessdate">. Retrieved <span class="nowrap">14 April</span> 2020</span>.</cite></span></li><li id="cite_note-11"> <span id="mw-reference-text-cite_note-11" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=125058  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=125058'" tppabs="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=125058" class="external text external">"Aldurazyme: FDA-Approved Drugs"</a>. <i>U.S. Food and Drug Administration (FDA)</i><span class="reference-accessdate">. Retrieved <span class="nowrap">14 April</span> 2020</span>.</cite></span></li><li id="cite_note-Clinical-12"> <span id="mw-reference-text-cite_note-Clinical-12" class="mw-reference-text"><a href="javascript:if(confirm('https://www.aldurazyme.com/healthcare/about-aldurazyme/clinical-trials.aspx  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.aldurazyme.com/healthcare/about-aldurazyme/clinical-trials.aspx'" tppabs="https://www.aldurazyme.com/healthcare/about-aldurazyme/clinical-trials.aspx" class="external text external">"Clinical Trials Summary."</a> Adurazyme (Laronidase) website. Accessed December 7, 2015.</span></li><li id="cite_note-13"> <span id="mw-reference-text-cite_note-13" class="mw-reference-text"><cite id="CITEREFHartsough2002" class="citation web cs1">Hartsough M (28 August 2002). <a href="javascript:if(confirm('https://web.archive.org/web/20101122150943/https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm083694.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20101122150943/https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm083694.pdf'" tppabs="https://web.archive.org/web/20101122150943/https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm083694.pdf" class="external text external">"Aldurazyme CMC Product Review"</a> <span class="cs1-format">(PDF)</span>. United States Food and Drug Administration. Archived from <a href="javascript:if(confirm('https://www.fda.gov/downloads/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/approvalapplications/therapeuticbiologicapplications/ucm083694.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/downloads/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/approvalapplications/therapeuticbiologicapplications/ucm083694.pdf'" tppabs="https://www.fda.gov/downloads/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/approvalapplications/therapeuticbiologicapplications/ucm083694.pdf" class="external text external">the original</a> <span class="cs1-format">(PDF)</span> on 22 November 2010.</cite></span></li><li id="cite_note-14"> <span id="mw-reference-text-cite_note-14" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://clinicaltrials.gov/ct2/show/NCT00418821  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://clinicaltrials.gov/ct2/show/NCT00418821'" tppabs="https://clinicaltrials.gov/ct2/show/NCT00418821" class="external text external">"A Study of the Effect of Aldurazyme (Laronidase) Treatment on Lactation in Female Patients With Mucopolysaccharidosis I (MPS I) and Their Breastfed Infants"</a>. <i>ClinicalTrials.gov</i>. 5 January 2007<span class="reference-accessdate">. Retrieved <span class="nowrap">14 April</span> 2020</span>.</cite></span></li><li id="cite_note-biomarin-15"> <span id="mw-reference-text-cite_note-biomarin-15" class="mw-reference-text"><a href="javascript:if(confirm('http://www.biomarin.com/products/aldurazyme/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.biomarin.com/products/aldurazyme/'" tppabs="http://www.biomarin.com/products/aldurazyme/" class="external text external">Aldurazyme (laronidase) for MPS I</a>. Biomarin website. Accessed December 6, 2015.</span></li><li id="cite_note-SEC_10-K_Feb_2011-16"> <span id="mw-reference-text-cite_note-SEC_10-K_Feb_2011-16" class="mw-reference-text"><a href="javascript:if(confirm('http://www.wikinvest.com/stock/BioMarin_Pharmaceutical_%28BMRN%29/Filing/10-K/2011/F94401752  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.wikinvest.com/stock/BioMarin_Pharmaceutical_%28BMRN%29/Filing/10-K/2011/F94401752'" tppabs="http://www.wikinvest.com/stock/BioMarin_Pharmaceutical_%28BMRN%29/Filing/10-K/2011/F94401752" class="external text external">United States Securities and Exchange Commission Form 10-K</a>. BioMarin Pharmaceuticals. February 24, 2011.  Accessed December 7, 2015.</span></li><li id="cite_note-17"> <span id="mw-reference-text-cite_note-17" class="mw-reference-text"><a href="javascript:if(confirm('http://www.accessdata.fda.gov/scripts/opdlisting/oopd/OOPD_Results_2.cfm?Index_Number=106097  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.accessdata.fda.gov/scripts/opdlisting/oopd/OOPD_Results_2.cfm?Index_Number=106097'" tppabs="http://www.accessdata.fda.gov/scripts/opdlisting/oopd/OOPD_Results_2.cfm?Index_Number=106097" class="external text external">FDA Orphan Drug Designations and Approvals</a>. FDA website. Accessed December 15, 2015.</span></li><li id="cite_note-D_2014-18"> <span id="mw-reference-text-cite_note-D_2014-18" class="mw-reference-text"><a href="javascript:if(confirm('http://www.wikinvest.com/stock/BioMarin_Pharmaceutical_(BMRN)/Filing/10-K/2015/F122541544  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.wikinvest.com/stock/BioMarin_Pharmaceutical_(BMRN)/Filing/10-K/2015/F122541544'" tppabs="http://www.wikinvest.com/stock/BioMarin_Pharmaceutical_(BMRN)/Filing/10-K/2015/F122541544" class="external text external">United States Securities and Exchange Commission Form 10-K</a>. BioMarin Pharmaceuticals. For the fiscal year ended December 31, 2014.  Accessed December 6, 2015.</span></li><li id="cite_note-patent-19"> <span id="mw-reference-text-cite_note-patent-19" class="mw-reference-text"><span class="citation patent" id="CITEREFKakkis_ED,_Tanamachi_B2020"><a href="javascript:if(confirm('https://worldwide.espacenet.com/textdoc?DB=EPODOC&IDX=WO9958691  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://worldwide.espacenet.com/textdoc?DB=EPODOC&IDX=WO9958691'" tppabs="https://worldwide.espacenet.com/textdoc?DB=EPODOC&IDX=WO9958691" class="external text external">WO<span> </span>application 9958691</a>,<span> </span>Kakkis ED, Tanamachi B,<span> </span>"Recombinant Î±-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof",<span> </span>published 18 November 1999 =,<span> </span> assigned to Harbor UCLA</span></span></li><li id="cite_note-20"> <span id="mw-reference-text-cite_note-20" class="mw-reference-text"><a href="javascript:if(confirm('http://www.wikinvest.com/stock/BioMarin_Pharmaceutical_%28BMRN%29/Filing/10-K/2013/F107185581  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.wikinvest.com/stock/BioMarin_Pharmaceutical_%28BMRN%29/Filing/10-K/2013/F107185581'" tppabs="http://www.wikinvest.com/stock/BioMarin_Pharmaceutical_%28BMRN%29/Filing/10-K/2013/F107185581" class="external text external">United States Securities and Exchange Commission Form 10-K</a>. BioMarin Pharmaceuticals. For the fiscal year ended December 31, 2012.  Accessed December 6, 2015.</span></li><li id="cite_note-21"> <span id="mw-reference-text-cite_note-21" class="mw-reference-text"><a href="javascript:if(confirm('http://www.wikinvest.com/stock/BioMarin_Pharmaceutical_%28BMRN%29/Net_Product_Revenues_Gross_Profit  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.wikinvest.com/stock/BioMarin_Pharmaceutical_%28BMRN%29/Net_Product_Revenues_Gross_Profit'" tppabs="http://www.wikinvest.com/stock/BioMarin_Pharmaceutical_%28BMRN%29/Net_Product_Revenues_Gross_Profit" class="external text external">BioMarin Pharmaceutical (BMRN)</a>. wikinvest. Accessed on December 6, 2015.</span></li><li id="cite_note-22"> <span id="mw-reference-text-cite_note-22" class="mw-reference-text"><a href="javascript:if(confirm('https://www1.magellanrx.com/media/604882/2016mrxtrendreport_final.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www1.magellanrx.com/media/604882/2016mrxtrendreport_final.pdf'" tppabs="https://www1.magellanrx.com/media/604882/2016mrxtrendreport_final.pdf" class="external free external">https://www1.magellanrx.com/media/604882/2016mrxtrendreport_final.pdf</a></span></li></ol></div></div>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Further_reading">Further reading</h2></summary>
    
<ul><li><cite id="CITEREFClarke2016" class="citation book cs1">Clarke LA (11 February 2016). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/books/NBK1162/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/books/NBK1162/'" tppabs="https://www.ncbi.nlm.nih.gov/books/NBK1162/" class="external text external">"Mucopolysaccharidosis Type I"</a>. <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/books/NBK1116/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/books/NBK1116/'" tppabs="https://www.ncbi.nlm.nih.gov/books/NBK1116/" class="external text external"><i>GeneReviews</i></a>. Seattle (WA): University of Washington. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/2372-0697  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/2372-0697'" tppabs="https://www.worldcat.org/issn/2372-0697" class="external text external">2372-0697</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/20301341  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/20301341'" tppabs="https://pubmed.ncbi.nlm.nih.gov/20301341" class="external text external">20301341</a>.</cite>&lt;/ref&gt;</li>
<li><cite class="citation web cs1"><a href="javascript:if(confirm('https://medlineplus.gov/ency/article/001204.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://medlineplus.gov/ency/article/001204.htm'" tppabs="https://medlineplus.gov/ency/article/001204.htm" class="external text external">"Mucopolysaccharidosis type I"</a>. <i>MedlinePlus</i>. NBK1162.</cite></li></ul>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="External_links">External links</h2></summary>
    
<ul><li><cite class="citation web cs1"><a href="javascript:if(confirm('https://druginfo.nlm.nih.gov/drugportal/name/laronidase  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://druginfo.nlm.nih.gov/drugportal/name/laronidase'" tppabs="https://druginfo.nlm.nih.gov/drugportal/name/laronidase" class="external text external">"Laronidase"</a>. <i>Drug Information Portal</i>. U.S. National Library of Medicine.</cite></li>
<li><a href="javascript:if(confirm('https://meshb.nlm.nih.gov/record/ui?name=Iduronidase  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://meshb.nlm.nih.gov/record/ui?name=Iduronidase'" tppabs="https://meshb.nlm.nih.gov/record/ui?name=Iduronidase" class="external text external">Iduronidase</a><span> at the US National Library of Medicine </span>Medical Subject Headings<span> (MeSH)</span></li></ul>

<div role="navigation" class="navbox" aria-labelledby="*_Metabolism:_carbohydrate_metabolism_*_proteoglycan_enzymes" style="padding:3px"><table class="nowraplinks hlist mw-collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="*_Metabolism:_carbohydrate_metabolism_*_proteoglycan_enzymes" style="font-size:114%;margin:0 4em">
<ul><li>Metabolism: carbohydrate metabolism</li>
<li>proteoglycan enzymes</li></ul>
</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%">glycosaminoglycan anabolism</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>L-xylulose reductase</li>
<li>L-gulonolactone oxidase</li>
<li>UDP-glucuronate 5'-epimerase</li>
<li>Xylosyltransferase</li>
<li>Sulfotransferase</li></ul>

<dl><dt><a href="Heparan_sulfate.htm" tppabs="https://ptable.com/wiki/compounds/A/Heparan_sulfate" title="Heparan sulfate">Heparan sulfate</a></dt>
<dd>EXT1</dd>
<dd>EXT2</dd></dl>

<dl><dt><a href="Chondroitin_sulfate.htm" tppabs="https://ptable.com/wiki/compounds/A/Chondroitin_sulfate" title="Chondroitin sulfate">Chondroitin sulfate</a></dt>
<dd>PAPSS1</dd>
<dd>PAPSS2</dd></dl>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">glycosaminoglycan catabolism</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th id="Hunter,_Hurler" scope="row" class="navbox-group" style="width:1%">Hunter, Hurler</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Iduronate-2-sulfatase</li>
<li><a href="Iduronidase.htm" tppabs="https://ptable.com/wiki/compounds/A/Iduronidase" title="Iduronidase">Iduronidase</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Sanfilippo, Sly</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Heparan sulfamidase</li>
<li>N-acetyltransferase</li>
<li>Alpha-N-acetylglucosaminidase</li>
<li><a href="Beta-glucuronidase.htm" tppabs="https://ptable.com/wiki/compounds/A/Beta-glucuronidase" title="Beta-glucuronidase">Glucuronidase</a></li>
<li>N-acetylglucosamine-6-sulfatase</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Morquio/Maroteaux-Lamy</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Arylsulfatase_B.htm" tppabs="https://ptable.com/wiki/compounds/A/Arylsulfatase_B" title="Arylsulfatase B">Arylsulfatase B</a></li>
<li>Galactosamine-6 sulfatase</li>
<li>Beta-galactosidase (GLB1)</li></ul>
</div></td></tr></tbody></table><div></div></td></tr></tbody></table></div>
<div role="navigation" class="navbox" aria-labelledby="Hydrolase:_sugar_hydrolases_(EC_3.2)" style="padding:3px"><table class="nowraplinks mw-collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Hydrolase:_sugar_hydrolases_(EC_3.2)" style="font-size:114%;margin:0 4em">Hydrolase: sugar hydrolases (EC 3.2)</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%">3.2.1: Glycoside hydrolases</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Disaccharidase</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Sucrase/Sucrase-isomaltase/Invertase</li>
<li>Maltase</li>
<li>Trehalase</li>
<li>Lactase</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Glucosidases</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Cellulase</li>
<li>Alpha-glucosidase
<ul><li>Acid</li>
<li>Neutral AB</li>
<li>Neutral C</li></ul></li>
<li>Beta-glucosidase
<ul><li>cytosolic</li></ul></li>
<li>Debranching enzyme</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Other</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Amylase
<ul><li>Alpha-amylase</li></ul></li>
<li>Chitinase</li>
<li>Lysozyme</li>
<li>Neuraminidase
<ul><li>NEU1</li>
<li>NEU2</li>
<li>NEU3</li>
<li>NEU4</li>
<li>Bacterial neuraminidase</li>
<li>Viral neuraminidase</li></ul></li>
<li>Galactosidases
<ul><li><a href="Alpha-galactosidase.htm" tppabs="https://ptable.com/wiki/compounds/A/Alpha-galactosidase" title="Alpha-galactosidase">Alpha</a></li>
<li>Beta</li></ul></li>
<li>alpha-Mannosidase</li>
<li><a href="Beta-glucuronidase.htm" tppabs="https://ptable.com/wiki/compounds/A/Beta-glucuronidase" title="Beta-glucuronidase">Glucuronidase</a>
<ul><li>Klotho</li></ul></li>
<li><a href="Hyaluronidase.htm" tppabs="https://ptable.com/wiki/compounds/A/Hyaluronidase" title="Hyaluronidase">Hyaluronidase</a></li>
<li>Pullulanase</li>
<li>Glucosylceramidase
<ul><li>lysosomal</li>
<li>non-lysosomal</li></ul></li>
<li>Galactosylceramidase</li>
<li>Alpha-N-acetylgalactosaminidase
<ul><li>NAGA</li></ul></li>
<li>Alpha-N-acetylglucosaminidase</li>
<li>Fucosidase</li>
<li>Hexosaminidase
<ul><li>HEXA</li>
<li>HEXB</li></ul></li>
<li><a href="Iduronidase.htm" tppabs="https://ptable.com/wiki/compounds/A/Iduronidase" title="Iduronidase">Iduronidase</a></li>
<li>Maltase-glucoamylase</li>
<li>Heparanase
<ul><li>HPSE2</li></ul></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">3.2.2: Hydrolysing<br>N-Glycosyl compounds</th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>DNA glycosylases: Oxoguanine glycosylase</li></ul>
</div></td></tr></tbody></table></div>
<div role="navigation" class="navbox" aria-labelledby="Enzymes" style="padding:3px"><table class="nowraplinks mw-collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Enzymes" style="font-size:114%;margin:0 4em">Enzymes</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%">Activity</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Active site</li>
<li>Binding site</li>
<li>Catalytic triad</li>
<li>Oxyanion hole</li>
<li>Enzyme promiscuity</li>
<li>Catalytically perfect enzyme</li>
<li>Coenzyme</li>
<li>Cofactor</li>
<li>Enzyme catalysis</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Regulation</th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Allosteric regulation</li>
<li>Cooperativity</li>
<li>Enzyme inhibitor</li>
<li>Enzyme activator</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Classification</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>EC number</li>
<li>Enzyme superfamily</li>
<li>Enzyme family</li>
<li>List of enzymes</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Kinetics</th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Enzyme kinetics</li>
<li>Eadie–Hofstee diagram</li>
<li>Hanes–Woolf plot</li>
<li>Lineweaver–Burk plot</li>
<li>Michaelis–Menten kinetics</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Types</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><b>EC1 Oxidoreductases</b> (list)</li>
<li><b>EC2 Transferases</b> (list)</li>
<li><b>EC3 Hydrolases</b> (list)</li>
<li><b>EC4 Lyases</b> (list)</li>
<li><b>EC5 Isomerases</b> (list)</li>
<li><b>EC6 Ligases</b> (list)</li>
<li><b>EC7 Translocases</b> (list)</li></ul>
</div></td></tr></tbody></table></div>




<style data-mw-deduplicate="TemplateStyles:r951705291">.mw-parser-output cite.citation{font-style:inherit}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .id-lock-free a,.mw-parser-output .citation .cs1-lock-free a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-limited a,.mw-parser-output .id-lock-registration a,.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-subscription a,.mw-parser-output .citation .cs1-lock-subscription a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration span{border-bottom:1px dotted;cursor:help}.mw-parser-output .cs1-ws-icon a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg*/);background-repeat:no-repeat;background-size:12px;background-position:right .1em center}.mw-parser-output code.cs1-code{color:inherit;background:inherit;border:inherit;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;font-size:100%}.mw-parser-output .cs1-visible-error{font-size:100%}.mw-parser-output .cs1-maint{display:none;color:#33aa33;margin-left:0.3em}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-right{padding-right:0.2em}.mw-parser-output .citation .mw-selflink{font-weight:inherit}</style>
    
</details><!--htdig_noindex--><div><div style="clear:both; background-image:linear-gradient(180deg, #E8E8E8, white); border-top: dashed 2px #AAAAAA; padding: 0.5em 0.5em 0.5em 0.5em; margin-top: 1em; direction: ltr;">
    This article is issued from <a class="external text" title="Last edited on 2020-08-01" href="javascript:if(confirm('https://en.wikipedia.org/wiki/?title=Iduronidase&oldid=970716993  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://en.wikipedia.org/wiki/?title=Iduronidase&oldid=970716993'" tppabs="https://en.wikipedia.org/wiki/?title=Iduronidase&oldid=970716993">Wikipedia</a>. The text is licensed under <a class="external text" href="javascript:if(confirm('https://creativecommons.org/licenses/by-sa/4.0/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://creativecommons.org/licenses/by-sa/4.0/'" tppabs="https://creativecommons.org/licenses/by-sa/4.0/">Creative Commons - Attribution - Sharealike</a>. Additional terms may apply for the media files.
</div>
</div><!--/htdig_noindex--></div>
        </div>
      </div>
    </div>
  </div>
  <script src="../-/j/js_modules/jsConfigVars.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/jsConfigVars.js" class=""></script>
  <script src="../-/j/js_modules/startup.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/startup.js" class=""></script>
<script src="../-/j/js_modules/jquery.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/jquery.js" class=""></script>
<script src="../-/j/js_modules/mediawiki.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/mediawiki.js" class=""></script>
<script src="../-/j/js_modules/site.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/site.js" class=""></script>
<script src="../-/j/js_modules/ext.cite.ux-enhancements.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/ext.cite.ux-enhancements.js" class=""></script>



</body></html>